DURYSTA (Bimatoprost SR) Drug Insight
“DURYSTA (Bimatoprost SR) Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about DURYSTA (Bimatoprost SR) for Glaucoma in the 6MM (the United States, and EU5). A detailed picture of the DURYSTA (Bimatoprost SR) for Glaucoma in the 6MM, i.e., the United States, and EU5 (Germany, France, Italy, Spain, and the United Kingdom) for the study period 2019–2032 is provided in this report along with a detailed description of the DURYSTA (Bimatoprost SR) for Glaucoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DURYSTA (Bimatoprost SR) market forecast, analysis for Glaucoma in the 6MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Glaucoma.
Drug Summary
DURYSTA (bimatoprost intracameral implant) is a prescription medicine to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma or high eye pressure (ocular hypertension).The solid, rod-shaped implant consists of the Prostaglandin Analog (PGA) bimatoprost within the company’s Novadur platform for drug delivery. After a prefilled, single-use applicator is used to place the implant intracamerally in the eye, the implant slowly releases the drug as the copolymer matrix biodegrades. The implant was designed to lower intraocular pressure (IOP) for at least 4 months.
Bimatoprost imitates the effects of prostamides, specifically prostaglandin F2α. The drug mildly stimulates aqueous humor outflow, relieving elevated intraocular pressure and decreasing the risk of optic nerve damage. It is thought that bimatoprost reduces intraocular pressure (IOP) in humans by causing an increase in the outflow of the aqueous humor via the trabecular meshwork and uveoscleral pathways. It achieves the above effects by decreasing tonographic resistance to aqueous humor outflow. It is currently available as a once-daily ophthalmic solution (Lumigan) for the reduction of elevated IOP in open-angle glaucoma or ocular hypertension.
Mechanism of Action
Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. Bimatoprost is believed to lower IOP in humans by increasing the outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional). Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Dosage and Administration
DURYSTA is an ophthalmic drug delivery system for a single intracameral administration of a biodegradable implant. The drug should not be re administered to an eye that received a prior dose. Intracameral implant containing 10 mcg of bimatoprost in a drug delivery system.
Scope of the Report
The report provides insights into:
A comprehensive product overview including the DURYSTA (Bimatoprost SR) description, mechanism of action, dosage and administration, research and development activities in Glaucoma.
Elaborated details on DURYSTA (Bimatoprost SR) regulatory milestones and other development activities have been provided in this report.
The report also highlights the DURYSTA (Bimatoprost SR) research and development activity in Glaucoma in detail across the United States, and Europe.
The report also covers the patents information with expiry timeline around DURYSTA (Bimatoprost SR).
The report contains forecasted sales of DURYSTA (Bimatoprost SR) for Glaucoma till 2032.
Comprehensive coverage of the late-stage emerging therapies for Glaucoma.
The report also features the SWOT analysis with analyst views for DURYSTA (Bimatoprost SR) in Glaucoma.
Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
DURYSTA (Bimatoprost SR) Analytical Perspective by DelveInsight
In-depth DURYSTA (Bimatoprost SR) Market Assessment
This report provides a detailed market assessment of DURYSTA (Bimatoprost SR) in Glaucoma in the 6MM, i.e., the United States EU5 (Germany, France, Italy, Spain, and the United Kingdom). This segment of the report provides forecasted sales data from 2022 to 2032.
DURYSTA (Bimatoprost SR) Clinical Assessment
The report provides the clinical trials information of DURYSTA (Bimatoprost SR) in Glaucoma covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
In the coming years, the market scenario for Glaucoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DURYSTA (Bimatoprost SR) dominance.
Other emerging products for Glaucoma are expected to give tough market competition to DURYSTA (Bimatoprost SR) and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DURYSTA (Bimatoprost SR) in Glaucoma.
Our in-depth analysis of the forecasted sales data of DURYSTA (Bimatoprost SR) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DURYSTA (Bimatoprost SR) in Glaucoma.
Key Questions
What is the product type, route of administration and mechanism of action of DURYSTA (Bimatoprost SR)?
What is the clinical trial status of the study related to DURYSTA (Bimatoprost SR) in Glaucoma and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DURYSTA (Bimatoprost SR) development?
What are the key designations that have been granted to DURYSTA (Bimatoprost SR) for Glaucoma?
What is the forecasted market scenario of DURYSTA (Bimatoprost SR) for Glaucoma?
What are the forecasted sales of DURYSTA (Bimatoprost SR) in the six major countries, including the United States, and Europe (Germany, France, Italy, Spain, and the United Kingdom?
What are the other emerging products available in Glaucoma and how are they giving competition to DURYSTA (Bimatoprost SR) for Glaucoma?
Which are the late-stage emerging therapies under development for the treatment of Glaucoma?
